$TELA
TELA Bio, Inc.

2024 Q3 Form 10-Q Financial Statement

#000155837024012060 Filed on August 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $18.96M $16.09M
YoY Change 25.94% 11.02%
Cost Of Revenue $6.099M $5.018M
YoY Change 30.88% 16.89%
Gross Profit $12.86M $11.07M
YoY Change 23.77% 8.55%
Gross Profit Margin 67.83% 68.81%
Selling, General & Admin $20.16M $20.32M
YoY Change 10.73% 12.58%
% of Gross Profit 156.75% 183.51%
Research & Development $2.068M $2.323M
YoY Change -12.67% -7.6%
% of Gross Profit 16.08% 20.98%
Depreciation & Amortization $263.0K $249.0K
YoY Change 19.55% 16.36%
% of Gross Profit 2.05% 2.25%
Operating Expenses $22.22M $22.64M
YoY Change 8.04% 10.12%
Operating Profit -$9.365M -$11.57M
YoY Change -8.01% 11.66%
Interest Expense -$1.344M -$1.331M
YoY Change -200.75% -202.54%
% of Operating Profit
Other Income/Expense, Net -$1.007M -$1.030M
YoY Change 29.77% 140.65%
Pretax Income -$10.37M -$12.60M
YoY Change -5.36% 16.77%
Income Tax
% Of Pretax Income
Net Earnings -$10.37M -$12.60M
YoY Change -5.34% 16.77%
Net Earnings / Revenue -54.71% -78.3%
Basic Earnings Per Share -$0.42 -$0.51
Diluted Earnings Per Share -$0.42 -$0.51
COMMON SHARES
Basic Shares Outstanding 24.71M 24.66M
Diluted Shares Outstanding 24.70M 24.66M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.30M $26.50M
YoY Change -70.27% -59.4%
Cash & Equivalents $17.30M $26.50M
Short-Term Investments
Other Short-Term Assets $2.009M $2.144M
YoY Change 21.02% 12.25%
Inventory $13.60M $13.37M
Prepaid Expenses
Receivables $11.22M $9.097M
Other Receivables $0.00 $0.00
Total Short-Term Assets $44.13M $51.11M
YoY Change -46.35% -42.68%
LONG-TERM ASSETS
Property, Plant & Equipment $2.423M $2.349M
YoY Change 38.54% 33.16%
Goodwill
YoY Change
Intangibles $1.834M $1.929M
YoY Change -17.16% -16.46%
Long-Term Investments
YoY Change
Other Assets $2.566M $2.701M
YoY Change
Total Long-Term Assets $8.884M $9.095M
YoY Change 75.4% 74.3%
TOTAL ASSETS
Total Short-Term Assets $44.13M $51.11M
Total Long-Term Assets $8.884M $9.095M
Total Assets $53.02M $60.20M
YoY Change -39.28% -36.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.479M $2.314M
YoY Change -19.8% 2.84%
Accrued Expenses $14.38M $12.68M
YoY Change 17.45% 17.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $16.86M $14.99M
YoY Change 9.94% 14.9%
LONG-TERM LIABILITIES
Long-Term Debt $40.97M $40.82M
YoY Change 1.5% 1.5%
Other Long-Term Liabilities $1.460M $1.528M
YoY Change 36.7% 35.94%
Total Long-Term Liabilities $42.43M $42.35M
YoY Change 2.41% 2.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.86M $14.99M
Total Long-Term Liabilities $42.43M $42.35M
Total Liabilities $59.29M $57.33M
YoY Change 4.44% 5.43%
SHAREHOLDERS EQUITY
Retained Earnings -$349.5M -$339.2M
YoY Change 13.47% 14.21%
Common Stock $25.00K $25.00K
YoY Change 4.17% 4.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.272M $2.870M
YoY Change
Total Liabilities & Shareholders Equity $53.02M $60.20M
YoY Change -39.28% -36.22%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$10.37M -$12.60M
YoY Change -5.34% 16.77%
Depreciation, Depletion And Amortization $263.0K $249.0K
YoY Change 19.55% 16.36%
Cash From Operating Activities -$8.983M -$10.70M
YoY Change 28.88% -5.03%
INVESTING ACTIVITIES
Capital Expenditures $122.0K $299.0K
YoY Change -12.86% 90.45%
Acquisitions
YoY Change
Other Investing Activities $0.00 $366.0K
YoY Change
Cash From Investing Activities -$122.0K $67.00K
YoY Change -12.86% -142.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 98.00K -5.000K
YoY Change 22.5% -100.01%
NET CHANGE
Cash From Operating Activities -8.983M -10.70M
Cash From Investing Activities -122.0K 67.00K
Cash From Financing Activities 98.00K -5.000K
Net Change In Cash -9.007M -10.64M
YoY Change 28.12% -130.4%
FREE CASH FLOW
Cash From Operating Activities -$8.983M -$10.70M
Capital Expenditures $122.0K $299.0K
Free Cash Flow -$9.105M -$11.00M
YoY Change 28.06% -3.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24675832
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24494675
dei Entity Central Index Key
EntityCentralIndexKey
0001561921
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39130
dei Entity Registrant Name
EntityRegistrantName
TELA Bio, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-5320061
dei Entity Address Address Line1
EntityAddressAddressLine1
1 Great Valley Parkway, Suite 24
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
320-2930
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
TELA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24713798
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26496000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46729000
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
298000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
416000
CY2024Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
9097000
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
9737000
CY2024Q2 us-gaap Inventory Net
InventoryNet
13372000
CY2023Q4 us-gaap Inventory Net
InventoryNet
13162000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2144000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2098000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
51109000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
71726000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2349000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1984000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1929000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2119000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1851000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1954000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2701000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
265000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
265000
CY2024Q2 us-gaap Assets
Assets
60204000
CY2023Q4 us-gaap Assets
Assets
78048000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2314000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1667000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12675000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15300000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
14989000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16967000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40817000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40515000
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1528000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1685000
CY2024Q2 us-gaap Liabilities
Liabilities
57334000
CY2023Q4 us-gaap Liabilities
Liabilities
59167000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24675832
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24494675
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
25000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
341897000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
339655000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
98000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
91000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339150000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-320889000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2870000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18881000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60204000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78048000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16091000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14494000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32694000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26403000
CY2024Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
4923000
CY2023Q2 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
4198000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
10095000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
8114000
CY2024Q2 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
95000
CY2023Q2 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
95000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
190000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
190000
CY2024Q2 us-gaap Gross Profit
GrossProfit
11073000
CY2023Q2 us-gaap Gross Profit
GrossProfit
10201000
us-gaap Gross Profit
GrossProfit
22409000
us-gaap Gross Profit
GrossProfit
18099000
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
16699000
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14577000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
34219000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
28043000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3621000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3472000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7450000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7106000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2323000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2514000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4716000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4566000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
22643000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
20563000
us-gaap Operating Expenses
OperatingExpenses
46385000
us-gaap Operating Expenses
OperatingExpenses
39715000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
7580000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11570000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10362000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16396000
us-gaap Operating Income Loss
OperatingIncomeLoss
-21616000
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1331000
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1298000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2663000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
2544000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
301000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
870000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
798000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1343000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1030000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-428000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1865000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1201000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12600000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10790000
us-gaap Net Income Loss
NetIncomeLoss
-18261000
us-gaap Net Income Loss
NetIncomeLoss
-22817000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24663234
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24663234
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23239262
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23239262
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24621310
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24621310
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21223639
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21223639
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12600000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10790000
us-gaap Net Income Loss
NetIncomeLoss
-18261000
us-gaap Net Income Loss
NetIncomeLoss
-22817000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-36000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
7000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-66000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12599000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10826000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18254000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22883000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
14384000
CY2024Q2 tela Apic Share Based Payment Arrangement Vesting Of Restricted Stock Units And Exercise Of Stock Options
ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions
6000
CY2024Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
11000
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1090000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-12600000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2870000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
18881000
tela Apic Share Based Payment Arrangement Vesting Of Restricted Stock Units And Exercise Of Stock Options
ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions
226000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
164000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
339000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
7000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2192000
us-gaap Net Income Loss
NetIncomeLoss
-18261000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
2870000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3141000
CY2023Q2 tela Apic Share Based Payment Arrangement Vesting Of Restricted Stock Units And Exercise Of Stock Options
ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions
56000
CY2023Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1000
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-36000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1294000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46341000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-10790000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40005000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
14305000
tela Apic Share Based Payment Arrangement Vesting Of Restricted Stock Units And Exercise Of Stock Options
ApicShareBasedPaymentArrangementVestingOfRestrictedStockUnitsAndExerciseOfStockOptions
100000
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
280000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-66000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2422000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46341000
us-gaap Net Income Loss
NetIncomeLoss
-22817000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40005000
us-gaap Profit Loss
ProfitLoss
-18261000
us-gaap Profit Loss
ProfitLoss
-22817000
us-gaap Depreciation
Depreciation
293000
us-gaap Depreciation
Depreciation
239000
us-gaap Paid In Kind Interest
PaidInKindInterest
302000
us-gaap Paid In Kind Interest
PaidInKindInterest
296000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
190000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
190000
tela Net Changes In Operating Lease Right Of Use Assets And Liabilities
NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities
47000
tela Net Changes In Operating Lease Right Of Use Assets And Liabilities
NetChangesInOperatingLeaseRightOfUseAssetsAndLiabilities
22000
us-gaap Inventory Write Down
InventoryWriteDown
908000
us-gaap Inventory Write Down
InventoryWriteDown
704000
us-gaap Share Based Compensation
ShareBasedCompensation
2192000
us-gaap Share Based Compensation
ShareBasedCompensation
2422000
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
7580000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-263000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1219000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1545000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2936000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-253000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-107000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
594000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
651000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2627000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-104000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
16000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
349000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25081000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22838000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
603000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
272000
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
5366000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4763000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-272000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
46354000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
226000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
339000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
280000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
164000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
51000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
46174000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
34000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20233000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23247000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46994000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42019000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26761000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65266000
us-gaap Interest Paid Net
InterestPaidNet
2361000
us-gaap Interest Paid Net
InterestPaidNet
2248000
tela Offering Costs In Accounts Payable And Accrued Expense And Other Current Liabilities
OfferingCostsInAccountsPayableAndAccruedExpenseAndOtherCurrentLiabilities
13000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
55000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
49000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The most significant judgments are employed in estimates used to determine the recoverability of the carrying value of the Company’s inventory. As future events and their effects cannot be determined with precision, actual results may differ significantly from these estimates.</p>
tela Incremental Costs Of Obtaining Contract
IncrementalCostsOfObtainingContract
0
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16091000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14494000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
32694000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26403000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3319087
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3088399
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6609000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9216000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2685000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2828000
CY2024Q2 tela Accrued Expenses Amount Due To Contract Manufacturer
AccruedExpensesAmountDueToContractManufacturer
1945000
CY2023Q4 tela Accrued Expenses Amount Due To Contract Manufacturer
AccruedExpensesAmountDueToContractManufacturer
2024000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
571000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
565000
CY2024Q2 tela Research And Development Expenses Payable Current
ResearchAndDevelopmentExpensesPayableCurrent
99000
CY2023Q4 tela Research And Development Expenses Payable Current
ResearchAndDevelopmentExpensesPayableCurrent
140000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
766000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
527000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12675000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15300000
CY2024Q2 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
2000000
CY2023Q4 us-gaap Debt Instrument Unamortized Premium
DebtInstrumentUnamortizedPremium
2000000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1183000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1485000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
40817000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
40515000
CY2024Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
88556
CY2024Q2 tela Equity Incentive Plans Number
EquityIncentivePlansNumber
2
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1090000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1294000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2192000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2422000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2162453
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
259900
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
38431
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
144782
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.07
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2239140
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.07
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M9D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2202926
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
11.10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y21D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1667647
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.60
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M26D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.732
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0429
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M20D
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-012060-index-headers.html Edgar Link pending
0001558370-24-012060-index.html Edgar Link pending
0001558370-24-012060.txt Edgar Link pending
0001558370-24-012060-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tela-20240630.xsd Edgar Link pending
tela-20240630x10q.htm Edgar Link pending
tela-20240630xex10d1.htm Edgar Link pending
tela-20240630xex10d1001.jpg Edgar Link pending
tela-20240630xex31d1.htm Edgar Link pending
tela-20240630xex31d2.htm Edgar Link pending
tela-20240630xex32d1.htm Edgar Link pending
tela-20240630xex32d2.htm Edgar Link pending
tela-20240630_cal.xml Edgar Link unprocessable
tela-20240630_def.xml Edgar Link unprocessable
tela-20240630_lab.xml Edgar Link unprocessable
tela-20240630_pre.xml Edgar Link unprocessable
tela-20240630x10q_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable